NKTR - Nektar Management to Present at Upcoming Investor Conferences

PR Newswire

SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:

• Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time
• Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time

The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events . The webcasts will be available for replay until July 6, 2024 and July 10, 2024 , respectively.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California . For further information, visit www.nektar.com and follow us on LinkedIn.

Contact:

For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661

For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com

SOURCE Nektar Therapeutics